Baxalta Brings Japan Suit Against Chugai Hemophilia Antibody
This article was originally published in PharmAsia News
Roche group member Chugai is facing legal action in Japan from Baxalta over claimed infringement of a hemophilia drug patent.
You may also be interested in...
Shire's first investor R&D day after its major acquisition of Baxalta earlier this year saw management keen to "bring confidence to the $20bn revenue target figure that we have stated," said CEO Flemming Ornskov. Shire's hemophilia focus, in particular, is facing some scrutiny.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.